Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial.
Yuuki ShimizuKazuhisa KondoRyo HayashidaKen-Ichiro SasakiMasanori OhtsukaYoshihiro FukumotoShinichiro TakashimaOto InoueSoichiro UsuiMasayuki TakamuraMasashi SakumaTeruo InoueTokuichiro NagataYoshihiro J AkashiYoshihiro YamadaTamon KatoKoichiro KuwaharaKaoru TatenoYoshio KobayashiRei ShibataToyoaki Muroharanull nullPublished in: Angiogenesis (2022)
Implantation of autologous ADRCs could be safe and effective for the achievement of therapeutic angiogenesis in the multicenter settings, as a result in no major adverse event, optimal survival rate, and limb salvage for patients with no-conventional option against critical limb ischemia. TRN: jRCTb040190118; Date: Nov. 24th, 2015.
Keyphrases
- endothelial cells
- induced apoptosis
- cell therapy
- vascular endothelial growth factor
- stem cells
- cross sectional
- mesenchymal stem cells
- double blind
- cell cycle arrest
- study protocol
- wound healing
- clinical trial
- bone marrow
- phase iii
- phase ii
- randomized controlled trial
- emergency department
- tissue engineering
- pi k akt
- placebo controlled